The FDA has approved Camcevi ETM, a long-acting formulation of leuprolide mesylate, for the treatment of advanced prostate cancer.

The FDA has approved 21 mg leuprolide mesylate (Camcevi ETM, Foresee Pharmaceuticals) as a ready-to-use long-acting injectable emulsion to be administered every 3 months for the treatment of advanced ...